Antiviral Properties of Human Milk

This article is for informational purposes only and is not medical advice. Full disclaimer →

In one sentence: A 2021 review catalogs at least 18 distinct classes of antiviral components in human milk — from antibodies to oligosaccharides to lipid-derived compounds — noting that synergistic interactions between components remain almost completely unstudied.

Wedekind SIS, Shenker NS · Microorganisms (2021)

PubMed 33807146 · DOI · PMC full text

Why this paper matters

The review catalogs human milk's antiviral architecture — a multi-component system whose individual pieces are increasingly investigated for therapeutic development against pathogens including SARS-CoV-2. The review is explicit that most evidence for individual components comes from in vitro work, that synergistic interactions between components remain almost completely unstudied, and that some clinical translation attempts have produced null findings — notably, bovine lactoferrin supplementation failed to reduce late-onset infection in preterm-infant RCTs. Clinical validation through controlled in vivo trials remains the critical open step.

Background

Human milk has long been recognized as more than nutrition — it is a living biofluid that transfers immune protection from mother to infant. For decades, researchers identified individual antimicrobial components like antibodies and lactoferrin, but a comprehensive mapping of the full antiviral arsenal in human milk was lacking. Most prior work focused on single components in isolation rather than the integrated system as a whole.

The COVID-19 pandemic accelerated research into human milk's antiviral properties, with studies finding SARS-CoV-2-specific IgA antibodies in approximately 80% of milk samples from recovered COVID-19 mothers. Simultaneously, advances in proteomics and glycomics are revealing previously unknown bioactive compounds. Two parallel 2021 reviews — Wedekind & Shenker in Microorganisms and Morniroli et al. in Nutrients — independently synthesized evidence across the full spectrum of antiviral mechanisms, providing the most comprehensive maps of human milk's antiviral architecture to date.

The Antiviral Arsenal

Your mother's milk contains more antiviral weapons than most pharmacies.

Human milk contains at least 18 distinct classes of antiviral compounds, from antibodies and oligosaccharides to oxysterols and bacteriophages.^{[1, 2]} The 2021 Wedekind & Shenker review catalogs immunoglobulins, HMOs, lactoferrin, lysozyme, lactadherin, tenascin C, extracellular vesicles, bacteriophages, cytokines, glycosaminoglycans, mucins, Lewis X, monolaurin, vitamin A, gangliosides, chondroitin sulphate, oxysterols, and the milk fat globule membrane as distinct antiviral defense systems. These operate through multiple mechanisms including direct viral neutralization, receptor blocking, immune modulation, and membrane disruption. A parallel 2021 review by Morniroli et al. in Nutrients similarly emphasizes that the totality of these properties and their synergistic interactions are not yet fully understood.

Approximately 90% of immunoglobulins in human milk are secretory IgA, which resists proteolytic digestion and can reach the infant's gut lumen intact.^[1] Secretory IgA (sIgA) is stabilized by binding to the secretory component, making it resistant to proteolysis. It neutralizes viruses by binding them directly and preventing adherence to mucosal epithelia. Importantly, the review notes that immunoglobulins may have limited antimicrobial function in isolation, underscoring the importance of the multi-component system rather than any single antibody class.

Human milk-derived extracellular vesicles contain 1,963 identified proteins and carry MHC class I and II molecules, representing a largely unexplored dimension of immune transfer.^[1] EVs are submicron-sized intercellular communication vehicles packed with regulatory molecules including miRNAs. A substantial protein overlap exists between different donors' milk EVs, suggesting conserved functional roles. These vesicles carry immune-relevant markers (MHC I/II, CD63, CD81, CD86) and their preparations inhibited pro-inflammatory IL-1 and IFN-γ production, suggesting immunomodulatory function. The breast tissue itself contributes to the EV pool, with immune cells likely producing compositional changes throughout lactation.

The Monolaurin & Lipid Defense System

The same fatty acid in coconut oil is one of breast milk's secret antiviral weapons — and it kills viruses by ripping apart their membranes.

Lauric acid accounts for roughly 4–6% of human breast milk fat in mature milk, rising from about 2.8% in colostrum — and its concentration increases progressively through the stages of lactation.^{[6, 10, 11]} A 2024 systematic review and meta-analysis by Liu et al. (n=3,507) found lauric acid content in human milk increases from 2.78% in colostrum to 4.97% in mature milk. A 2022 study by Sarkadi et al. analyzing 69 mothers found lauric acid at 4–6% of total fatty acids in mature milk. These data from high-quality, peer-reviewed sources supersede earlier estimates. Lauric acid is converted in the body to monolaurin (glycerol monolaurate), which demonstrates broader antimicrobial activity than the parent fatty acid. The FDA classifies monolaurin as Generally Recognized As Safe (GRAS), as documented in Subroto & Indiarto 2020.

Glycerol monolaurate (GML) is virucidal against HIV-1, yellow fever virus, mumps virus, and Zika virus, and it specifically blocks HIV-1 entry at the coreceptor binding step after CD4 engagement.^[7] Welch et al. (2020) demonstrated in mBio that GML restricts HIV-1 viral entry post-CD4 engagement at the coreceptor binding step. Immature viral particles that had not undergone proteolytic maturation were more sensitive to GML. Previous macaque studies showed GML reduces SIV transmission and alters immune responses, suggesting therapeutic potential beyond in vitro settings. The authors highlight GML as a candidate for reducing sexually transmitted infections, noting that 340 million STIs are acquired annually.

Antiviral and antibacterial activity in the infant stomach comes from intragastric digestion of milk triglycerides into monoglycerides and fatty acids — and in a study of low birthweight infants, this effect was equally strong with formula.^[4] A pivotal 1990 study by Isaacs et al. studied 21 low birthweight (LBW) infants. While fresh milk and formula showed no antiviral activity before feeding, gastric aspirates 1–3 hours post-feeding reduced titers of enveloped viruses and killed bacteria. There was no consistent difference between human milk and conventional LBW formula. Importantly, this finding was specific to low birthweight infants and should not be generalized without caution — the unique advantage of human milk likely lies in its non-lipid components and their synergistic interactions, not lipid digestion per se.

GML inhibits human T cell signaling by disrupting plasma membrane lipid dynamics, preventing formation of LAT, PLC-γ, and AKT signaling microclusters and significantly reducing production of IL-2, IFN-γ, TNF-α, and IL-10.^[8] Zhang, Sandouk & Houtman (2016) in Scientific Reports showed that GML alters the order and disorder dynamics of the T cell plasma membrane, preventing LAT, PLC-γ, and AKT microclusters from forming. This selectively inhibits TCR-induced phosphorylation of PI3K and AKT and abrogates calcium influx. The paper explicitly confirms significant reductions in IL-2, IFN-γ, TNF-α, and IL-10 production. This dual profile — killing pathogens while dampening inflammatory T cell responses — makes GML unique among antimicrobial lipids.

When both mother and infant are ill with cold-like symptoms, the proportions of lauric acid (C12:0) and capric acid (C10:0) in breast milk are significantly lower than during healthy periods.^[5] Gardner et al. (2017) analyzed milk from 26 mothers during health and illness using gas chromatography. When both were symptomatic, antimicrobial medium-chain fatty acids (capric and lauric) decreased while palmitic acid increased. When only the infant was unwell, palmitoleic and stearic acid proportions rose. The observed differences were small (less than 0.5%), the study involved only 26 participants, and the authors themselves describe the findings as suggestive rather than definitive — indicating a possible dynamic response without confirming functional significance.

Sugar Shields and Molecular Decoys

Human milk oligosaccharides don't feed the baby — they trick viruses into attacking the wrong target.

Human milk contains over 100 different oligosaccharides at concentrations up to 20–25 g/L in early milk — making HMOs the third largest solid component after lactose and lipids, and a component almost entirely absent from infant formula.^{[1, 12]} HMOs are a structurally diverse family of free oligosaccharides unique to human milk. Their composition varies between women, across lactation, and even by season. Lactose serves as the template at the reducing end and can be elongated, fucosylated, or sialylated to create enormous structural diversity. Infant formula currently contains only trace amounts of these sugars compared to the 8–20 grams per liter in human milk, making HMOs one of the most significant qualitative differences between breast milk and formula.

2'-Fucosyllactose (2'FL) HMOs can block multiple strains of norovirus by mimicking the histo-blood group antigens that the virus uses to bind to gut cells.^{[1, 12]} X-ray crystallography has revealed that HMOs interact with norovirus by mimicking HBGAs — the carbohydrate-based antigens on mucosal surfaces that noroviruses use for cell entry. The HMO 2'FL can bind to both GI and GII HBGA pockets, and high-molecular mass HMOs show even higher binding affinity due to greater avidity of α-fucose residues. These sugar molecules essentially act as decoy receptors, intercepting viruses before they reach gut cells. The same 'receptor decoy' mechanism applies to influenza, rotavirus, RSV, and HIV.

The Breastfeeding Paradox and HIV

Mixed feeding is more dangerous than exclusive breastfeeding for HIV-exposed infants — and science is only now understanding why.

According to the 2021 review, 10–15% of exclusively breastfed infants become infected from an HIV-positive mother without antiretroviral therapy; with modern ART and undetectable maternal viral load the risk drops below 0.5%.^[1] The review reports that without antiretroviral therapy, HIV transmission through exclusive breastfeeding occurs in approximately 10–15% of infants born to HIV-positive mothers. Modern ART regimens that achieve undetectable maternal viral load reduce this postnatal risk to below 0.5%. The review also notes that even small amounts of formula alongside breastfeeding may disrupt the integrated protective environment that breast milk's multiple bioactive components create, suggesting a possible mechanism for the WHO's recommendation of exclusive breastfeeding for HIV-exposed infants. The specific causal pathway remains hypothesis-level in the source.

Multiple GAG types in human milk — with chondroitin sulphate comprising approximately 55% of total GAGs — inhibit HIV's gp120 glycoprotein from binding to CD4 receptors, and this effect survives digestion with lytic enzymes.^[1] Glycosaminoglycans in human milk block a critical first step in HIV infection: the binding of viral envelope glycoprotein gp120 to the host CD4 receptor. This inhibitory effect is maintained even after exposure to digestive lytic enzymes, specifically for heparin, heparan sulphate, and dermatan sulphate. GAG concentrations peak around day 4 of lactation with a strong decrease between days 4–10 in both term and preterm infants.

Lactoferrin — The Swiss Army Knife Protein

One protein in breast milk fights viruses in at least three completely different ways — but clinical trials have delivered a sobering reality check.

Lactoferrin reaches concentrations up to 7 g/L in colostrum, declines over the initial months of lactation, then — according to one longitudinal study (Perrin et al.) — increases again as lactation continues into the second year.^[1] Lactoferrin is a multifunctional iron-binding protein whose antiviral activity operates independently of its iron-binding capacity. It can bind directly to viral particles, bind to host cell receptors to prevent viral docking, and upregulate the innate immune system through NK cells and macrophages — making it a triple-threat antiviral agent. The biphasic concentration pattern (high in colostrum, declining, then rising again) is based on a single longitudinal study (Perrin et al.) cited within the review, rather than replicated across multiple datasets.

Lactoferrin blocks SARS-CoV infection by competitively binding to heparan sulphate proteoglycans (HSPGs) on host cells — but the review explicitly states no evidence yet exists confirming this mechanism works against SARS-CoV-2.^{[1, 9]} HSPGs serve as docking sites for many viruses on target cells, and lactoferrin occupies these sites competitively. This has been demonstrated for SARS-CoV and several other viruses. However, the Wedekind & Shenker review explicitly flags the absence of SARS-CoV-2 evidence as a research gap. A separate 2024 review in the Journal of Functional Foods does confirm that milk whey proteins more broadly can inhibit SARS-CoV-2 replication in infected cells, but this is a distinct claim from the specific HSPG-blocking mechanism.

Randomized controlled trials and meta-analyses have found that bovine lactoferrin supplementation does NOT prevent late-onset infection in preterm infants — a critical null finding from clinical translation.^[1] A key RCT found that external lactoferrin supplementation did not reduce late-onset infection in preterm infants, and meta-analysis confirmed bovine LF supplementation provides no convincing evidence to reduce late-onset neonatal sepsis. Possible explanations include structural differences between human and bovine lactoferrin, the confounding effect of mixing LF with various fluids including formula in the trials, and the fundamental challenge of replicating the integrated function of a native milk component when delivered in isolation. This highlights the persistent gap between in vitro promise and clinical reality.

What's Next — Therapeutic Frontiers

We've mapped human milk's antiviral weapons and active research into their therapeutic use is already underway — but clinical proof remains elusive.

The Milk Fat Globule Membrane (MFGM) is a tri-layer structure of polar lipids, glycolipids, and proteins that exhibits antiviral properties — and formula supplemented with bovine MFGM shows promising results for neurodevelopment and infection defense.^{[1, 3, 13]} MFGM proteins have demonstrated antiviral activity, and sphingomyelin within MFGM offers additional benefits including enhanced neuronal development and protection against bacterial infections. A 2025 FSANZ regulatory assessment confirmed that MFGM-enriched whey protein concentrate in infant formula supports development of a gut microbiome resembling that of breastfed infants, though available evidence was deemed insufficient to definitively confirm improvements in cognitive function. This represents one of the most commercially actionable findings from the broader human milk literature.

Caveats and open questions

What this paper doesn't settle

Almost all antiviral evidence for individual human milk components comes from in vitro studies, which may not reflect in vivo conditions. The primary 2021 review explicitly acknowledges that some components (including tenascin C) may not be present in sufficient concentrations in human milk to mediate effective antiviral activity in vivo. The synergistic interactions between components — which may be the key to clinical efficacy — remain almost completely unstudied. The specific antiviral role of monolaurin within the context of human milk has never been directly studied. The 80% IgA figure for COVID recovery relies on primary studies (Fox et al., Pace et al.) cited second-hand in the review. There is also scant research on HMO concentrations beyond 2 years of lactation.

The honest skeptical read

A critical 1990 study by Isaacs et al. found that antiviral and antibacterial activity in gastric aspirates from low birthweight infants was equally strong whether infants were fed human milk or conventional LBW formula — suggesting that lipid-mediated antimicrobial effects at least partly come from intragastric digestion of any fat source. This challenges simple narratives that human milk lipids provide unique antiviral advantages. Furthermore, RCTs of bovine lactoferrin supplementation in preterm infants found no benefit for preventing late-onset infection, and meta-analysis confirmed this lack of efficacy — highlighting the persistent gap between impressive in vitro results and clinical outcomes in the lactoferrin literature specifically.

Common misconception

A widespread misconception is that breast milk's immune benefits are limited to antibody transfer. In reality, antibodies are just one of at least 18 distinct antiviral systems, and the review notes immunoglobulins 'may have limited antimicrobial function in isolation.' Another misconception is that the antiviral components in breast milk are fragile and destroyed by digestion — in fact, sIgA is resistant to proteolysis, GAG-mediated HIV inhibition survives enzymatic digestion, and components like TGF-β are actually activated by the low pH of the stomach. A third misconception is that the therapeutic potential of milk-derived compounds is entirely unexplored — active research including 2024 clinical reviews already documents milk protein activity against SARS-CoV-2 and synergy with approved antivirals.